COMPARISON IMMUNOHISTOCHEMISTRY AND REAL-TIME PCR METHODS TO DETERMINE THE HER2 STATUS ANNOTATION
Keywords:
HER2, SYBR Green, breast cancer, PCRAbstract
This study is aimed to carry out two methods of quantitative polymerase chain reaction (PCR), with the use of intercalating SYBR Green dye to determine the amount of gene HER2 (human epidermal receptor) in breast tumors. The experiments were carried out in 8 validated samples of breast cancer. In the samples of breast cancer, a comparison of the results of immunohistochemistry (IHC) and SYBR Green rt-PCR is 87.5% identical. Real-time PCR with SYBR Green allowing obtain a minimum number of false negative conclusions about the absence of marker expression in tumor tissue.
References
Fukushige SI, Matsubara KI, Yoshida M. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Molecular and Cellular Biology. 1986;6(3):955-958
Stern DF, Heffernan PA, Weinberg RA. P185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Molecular and Cellular Biology. 1986;6(5):1729-1740.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712
Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990, 50:4332– 4337
Parkes HC, Lillycrop K, Howell A, Craig RK: C-erbB2 mRNA expression in human breast tumors: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 1990, 61:39 – 45
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
Bang YJ, Van Custem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687-697.
Sauter G, Lee J, Barrlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 2009;27:1323-1333.
Moerland E, van Hezik RL, van der Aa TC, van Beek MW, van den Brule AJ. Detection of HER2 amplification in breast carcinomas: comparison of Multiplex Ligation-dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with automated spot counting. Cell Oncol. 2006;28:151-159.
Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridization using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005;58:710-714.
Persson K, Pandis N, Mertens F, Borg A, Baldetorp B, Killander D, Isola J: Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer 1999, 25:115–122
Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R: Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2002, 15:137–145
Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg L, Hanna W, Wittwer C, Seth A, and Lyon A: Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. JMD 2003, 5:184-190
Matsenko NU, Rijikova VS, and Kovalenko SP: Comparison of SYBR Green I and TaqMan real-time PCR formats for the analysis of HER2 gene dose in human breast tumors. Bulletin of Experimental Biology and Medicine 2008, 145:240-244
